First Trust Advisors
NMRA icon

First Trust Advisors’s Neumora Therapeutics NMRA Stock Holding History

First Trust Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-26,770
Closed -$378K – 2399
2023
Q3 		$378K Buy
+26,770
New +$335K ﹤0.01% 2202

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Trust Advisors's NMRA Position: Q4 2023 in Review

First Trust Advisors sold out of Neumora Therapeutics (NMRA) in Q4 2023, closing a stake of 26,770 shares — an estimated $378K sold.

First Trust Advisors first reported a position in NMRA in Q3 2023 and held it in 1 quarter. The position peaked at $378K in Q3 2023. 60 funds tracked by Wall St. Rank hold NMRA as of Q4 2023.

  • First Trust Advisors reported no remaining Neumora Therapeutics position as of Q4 2023 after selling out during the quarter.
  • First Trust Advisors sold 26,770 Neumora Therapeutics shares in Q4 2023, an estimated $378K.
  • First Trust Advisors first reported a position in Neumora Therapeutics in Q3 2023 and held it in 1 quarter.
  • First Trust Advisors's Neumora Therapeutics position peaked at $378K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2023.

Based on First Trust Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.